| 9.57 -0.605 (-5.95%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.78 | 1-year : | 16.09 |
| Resists | First : | 11.8 | Second : | 13.78 |
| Pivot price | 9.87  |
|||
| Supports | First : | 8.83 | Second : | 7 |
| MAs | MA(5) : | 9.95 |
MA(20) : | 9.25 |
| MA(100) : | 10.27 |
MA(250) : | 9.73 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 61.5 |
D(3) : | 63.6 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 17.17 | Low : | 6.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BGM ] has closed above bottom band by 41.9%. Bollinger Bands are 4.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.9 - 9.98 | 9.98 - 10.03 |
| Low: | 9.29 - 9.37 | 9.37 - 9.43 |
| Close: | 9.46 - 9.59 | 9.59 - 9.68 |
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Wed, 01 Oct 2025
Is BGM Group Ltd. stock cheap compared to fundamentals - Weekly Trading Summary & AI Enhanced Trading Signals - newser.com
Wed, 01 Oct 2025
What’s next for BGM Group Ltd. stock price - July 2025 Levels & Reliable Breakout Forecasts - newser.com
Wed, 24 Sep 2025
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday - Benzinga
Wed, 24 Sep 2025
BGM Group: I Think I Found An Undervalued Stock (NASDAQ:BGM) - Seeking Alpha
Thu, 24 Jul 2025
BGM Group Ltd Reports Increased Revenue and Asset Growth in H1 2025 - TipRanks
Tue, 22 Jul 2025
Insiders the biggest winners as BGM Group Ltd.'s (NASDAQ:BGM) market cap rises to US$2.1b - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 181 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 7.2 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.85 |
| Profit Margin | -26.4 % |
| Operating Margin | -5.5 % |
| Return on Assets (ttm) | -3.9 % |
| Return on Equity (ttm) | -16.6 % |
| Qtrly Rev. Growth | -57 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.16 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -33 |
| PEG Ratio | 0 |
| Price to Book value | 5.17 |
| Price to Sales | 57.86 |
| Price to Cash Flow | 583.96 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 2.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|